Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 7/20 | 0.50 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.48 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22235083 | 0.93 | FDPS (0.47) | FDPSBTN3A1PDE3ACHRNB2CHRNA4 | |
| SCHEMBL28386449 | 0.92 | LMNA (0.46) | FDPSBTN3A1PDE3ACHRNB2CHRNA4 | |
| SCHEMBL28384938 | 0.90 | GAA (0.46) | FDPSBTN3A1PDE3ACHRNB2CHRNA4 | |
| SCHEMBL30102567 | 0.85 | FDPS (0.56) | FDPSBTN3A1PDE3ANAPRTCYP1A2 | |
| SCHEMBL207656 | 0.85 | FDPS (0.56) | FDPSBTN3A1PDE3ANAPRTCYP1A2 | |
| SCHEMBL8394763 | 0.84 | FDPS (0.54) | FDPSBTN3A1PDE3ANAPRTCYP1A2 | |
| SCHEMBL17034259 | 0.82 | FDPS (0.53) | FDPSBTN3A1PDE3ANAPRTHDAC1 | |
| SCHEMBL19353234 | 0.81 | LMNA (0.46) | FDPSBTN3A1PDE3ACHRNB2CHRNA4 | |
| SCHEMBL17034258 | 0.81 | LMNA (0.46) | FDPSBTN3A1PDE3ACHRNB2CHRNA4 | |
| SCHEMBL22235085 | 0.80 | FDPS (0.50) | FDPSBTN3A1PDE3ANAPRTHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088941-B2 | Glycogen synthase kinase-3 inhibitors | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2012-01-03 | — | — | US | disclosed |
| US-20080312188-A1 | Glycogen synthase kinase-3 inhibitors | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2008-12-18 | — | — | US | disclosed |
| US-7378432-B2 | Glycogen synthase kinase-3 inhibitors | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2008-05-27 | — | — | US | disclosed |
| EP-1638557-A4 | GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | UNIV TEL AVIV FUTURE TECH DEV (IL) | 2007-11-07 | — | — | EP | disclosed |
| EP-1824468-A2 | GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | Tel Aviv University Future Technology Development L.P. (IL) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006054298-A2 | GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2006-05-26 | — | — | WO | disclosed |
| US-20060069066-A1 | 3-(4-(3-guanidinophenyl)-1,2,3-triazol-1-yl)benzyl phosphoric acid hydrochloride; obesity, non-insulin dependent diabetes mellitus, insulin-dependent condition, affective disorder, neurodegenerative diseases, psychotic disease; compounds having hydrophobic moiety to a terminus of a peptide GSK-3 | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. | 2006-03-30 | — | — | US | disclosed |
| EP-1638557-A2 | GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | Tel Aviv University Future Technology Development L.P. (IL) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005000192-A2 | GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069066-A1 | 3-(4-(3-guanidinophenyl)-1,2,3-triazol-1-yl)benzyl phosphoric acid hydrochloride; obesity, non-insulin dependent diabetes mellitus, insulin-dependent condition, affective disorder, neurodegenerative diseases, psychotic disease; compounds having hydrophobic moiety to a terminus of a peptide GSK-3 | GSK3A, GSK3B, PYGB | FDPS 3703/4885BTN3A1 115/4885PDE3A 1896/4885 |
| US-20080312188-A1 | Glycogen synthase kinase-3 inhibitors | GSK3B, GSK3A, GSKIP | FDPS 1253/4885BTN3A1 871/4885PDE3A 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.